Novartis CEO Vas Narasimhan has joined the board of directors at artificial intelligence company Anthropic, according to sources familiar with the matter. The move, first reported by STAT, highlights the growing convergence between pharmaceutical giants and AI developers in drug discovery and healthcare innovation.
Narasimhan, who has led Novartis since 2018, brings decades of pharmaceutical leadership to Anthropic, an AI safety startup founded by former OpenAI researchers. Analysts suggest the appointment reflects Novartis’ strategic interest in leveraging generative AI for clinical trials and drug development. “This is a logical next step after their existing AI partnerships,” said a biotech analyst who requested anonymity due to client relationships.
Anthropic has recently expanded its healthcare initiatives, including a reported collaboration with Alphabet’s Isomorphic Labs. The company’s Claude AI models are being tested for biomedical research applications by several pharmaceutical firms. Industry officials note that Narasimhan’s board seat could facilitate tighter integration between Anthropic’s technology and Novartis’ R&D pipeline.
The appointment comes during a period of heightened activity at the pharma-AI intersection. Earlier this week, Revolution Medicines secured $2 billion in funding for its cancer therapeutics program, while Structure Therapeutics’ executive hire sparked acquisition speculation. Some experts caution that the AI-pharma partnership boom may face regulatory scrutiny. “FDA guidance on AI-assisted drug development remains embryonic,” noted a former FDA official now at a law firm.